JP2014502628A5 - - Google Patents

Download PDF

Info

Publication number
JP2014502628A5
JP2014502628A5 JP2013548903A JP2013548903A JP2014502628A5 JP 2014502628 A5 JP2014502628 A5 JP 2014502628A5 JP 2013548903 A JP2013548903 A JP 2013548903A JP 2013548903 A JP2013548903 A JP 2013548903A JP 2014502628 A5 JP2014502628 A5 JP 2014502628A5
Authority
JP
Japan
Prior art keywords
cells
million
dose
cell
million cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013548903A
Other languages
English (en)
Japanese (ja)
Other versions
JP6018081B2 (ja
JP2014502628A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2012/000097 external-priority patent/WO2012095743A2/en
Publication of JP2014502628A publication Critical patent/JP2014502628A/ja
Publication of JP2014502628A5 publication Critical patent/JP2014502628A5/ja
Application granted granted Critical
Publication of JP6018081B2 publication Critical patent/JP6018081B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013548903A 2011-01-12 2012-01-12 自己免疫および炎症性疾患におけるリンパ系内投与用の脂肪由来間葉系幹細胞 Active JP6018081B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11250025.1 2011-01-12
EP11250025 2011-01-12
PCT/IB2012/000097 WO2012095743A2 (en) 2011-01-12 2012-01-12 Methods and compositions for use in intralymphatic cellular therapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016190665A Division JP2017035094A (ja) 2011-01-12 2016-09-29 自己免疫および炎症性疾患におけるリンパ系内投与用の脂肪由来間葉系幹細胞

Publications (3)

Publication Number Publication Date
JP2014502628A JP2014502628A (ja) 2014-02-03
JP2014502628A5 true JP2014502628A5 (enExample) 2015-03-05
JP6018081B2 JP6018081B2 (ja) 2016-11-02

Family

ID=45558792

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013548903A Active JP6018081B2 (ja) 2011-01-12 2012-01-12 自己免疫および炎症性疾患におけるリンパ系内投与用の脂肪由来間葉系幹細胞
JP2016190665A Pending JP2017035094A (ja) 2011-01-12 2016-09-29 自己免疫および炎症性疾患におけるリンパ系内投与用の脂肪由来間葉系幹細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016190665A Pending JP2017035094A (ja) 2011-01-12 2016-09-29 自己免疫および炎症性疾患におけるリンパ系内投与用の脂肪由来間葉系幹細胞

Country Status (6)

Country Link
US (1) US20140154274A1 (enExample)
EP (1) EP2663316A2 (enExample)
JP (2) JP6018081B2 (enExample)
KR (1) KR101900664B1 (enExample)
ES (1) ES2479544T1 (enExample)
WO (1) WO2012095743A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
CA2623353C (en) 2005-09-23 2017-02-21 Cellerix, S.L. Cell populations having immunoregulatory activity, method for isolation and uses
US20160120910A1 (en) * 2013-06-25 2016-05-05 Tigenix S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
US20150104470A1 (en) * 2013-10-11 2015-04-16 Neil H. Riordan Immune modulation by peri-lymphatic or intra-lymphatic cell therapy
US20170121685A1 (en) * 2015-11-02 2017-05-04 Tigenix S.A.U. Mesenchymal stem cell-derived exosomes and their uses
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
CN109152764A (zh) * 2016-05-06 2019-01-04 学校法人大阪医科药科大学 用于增强炎性疾病治疗用干细胞的功能的包封抑制素的纳米粒子制剂、以及含有其的炎性疾病治疗用功能增强干细胞
JP6788003B2 (ja) * 2016-08-26 2020-11-18 学校法人大阪医科薬科大学 スタチン封入ナノ粒子を含有する機能増強幹細胞を含む炎症性疾患治療用細胞製剤
CN114555140A (zh) 2019-10-17 2022-05-27 泰尔茂株式会社 用于处置炎性疾病的细胞培养物
WO2021207192A1 (en) * 2020-04-08 2021-10-14 Figene, Llc Methods and compositions for allergy and asthma treatment using fibroblasts

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694038B2 (en) * 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
CA2493081C (en) * 2002-07-12 2013-04-23 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
EP2298863B1 (en) * 2004-03-22 2015-07-22 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
EP1729788B1 (en) * 2004-03-30 2009-11-25 Boston Scientific Limited Restenosis therapy using mesenchymal stem cells
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
CA2623353C (en) 2005-09-23 2017-02-21 Cellerix, S.L. Cell populations having immunoregulatory activity, method for isolation and uses
EP2303293A1 (en) * 2008-05-27 2011-04-06 Pluristem Ltd. Methods of treating inflammatory colon diseases
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
CN102428179A (zh) * 2009-03-06 2012-04-25 国立大学法人三重大学 用于增强t细胞功能的方法
WO2011004264A1 (en) * 2009-07-09 2011-01-13 Cellerix Sa Methods and compositions for use in cellular therapies
WO2011047345A2 (en) * 2009-10-15 2011-04-21 Tai June Yoo Methods of treating diseases of conditions using mesenchymal stem cells

Similar Documents

Publication Publication Date Title
Huang et al. Potential therapeutic strategies for skeletal muscle atrophy
Kircheis et al. NF-κB pathway as a potential target for treatment of critical stage COVID-19 patients
Fernandez-Francos et al. Mesenchymal stem cell-based therapy as an alternative to the treatment of acute respiratory distress syndrome: current evidence and future perspectives
Trompette et al. Dietary fiber confers protection against flu by shaping Ly6c− patrolling monocyte hematopoiesis and CD8+ T cell metabolism
Marchezan et al. Immunological dysfunction in autism spectrum disorder: a potential target for therapy
JP2012532859A5 (enExample)
Wang et al. Regulation of inflammatory cytokine storms by mesenchymal stem cells
Liu et al. Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis
ES2479544T1 (es) Células madre mesenquimales derivadas de tejido adiposo para administración intralinfática en enfermedades autoimmunes e inflamatorias
Kulakova et al. The contribution of macrophage plasticity to inflammatory arthritis and their potential as therapeutic targets
RU2012104529A (ru) Способы и композиции для применения в клеточной терапии
Cai et al. Mesenchymal stem cells and their exocytotic vesicles
Wu et al. Current understanding of mesenchymal stem cells in liver diseases
Nam et al. Intraperitoneal infusion of mesenchymal stem cell attenuates severity of collagen antibody induced arthritis
Harrell et al. Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in the Treatment of SARS‐CoV‐2‐Induced Acute Respiratory Distress Syndrome
Gardin et al. Could mesenchymal stem cell-derived exosomes be a therapeutic option for critically Ill COVID-19 patients?
JP2015517488A5 (enExample)
BR112014010417A2 (pt) Métodos para o tratamento de cânceres com o uso de formulações orais de análogos de citidina
Gu et al. Endothelium‐derived engineered extracellular vesicles protect the pulmonary endothelial barrier in acute lung injury
Wang et al. Honeysuckle‐Derived Nanovesicles Regulate Gut Microbiota for the Treatment of Inflammatory Bowel Disease
Fang et al. Mechanisms of potential therapeutic utilization of mesenchymal stem cells in COVID-19 treatment
JP2015502135A5 (enExample)
Koseoglu New treatment modalities in Alzheimer's disease
Shi et al. Mesenchymal stem cells and connective tissue diseases: From bench to bedside
Chen et al. Decoding tumor-fibrosis interplay: mechanisms, impact on progression, and innovative therapeutic strategies